Diagnostic and prognostic evaluation of phenotypic markers TRAF1, MUM1, BCL2 and CD15 in cutaneous CD30-positive lymphoproliferative disorders

British Journal of Dermatology

Volumn 161, Issue 1, 2009, Pages 121-127

  Benner, M F ^a   Jansen, P M ^a   Meijer, C J L M ^b   Willemze, R ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

CD30; Cutaneous; Diagnostic; Immunohistochemistry; Lymphoma; Prognostic

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CD15 ANTIGEN; CD30 ANTIGEN; INTERFERON REGULATORY FACTOR 4; PROTEIN BCL 2; TUMOR MARKER; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 1;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; EVALUATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; LYMPHOMATOID PAPULOSIS; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MYCOSIS FUNGOIDES; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SCHOOL CHILD; SKIN BIOPSY; SURVIVAL RATE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD15; ANTIGENS, CD30; BIOPSY; CHILD; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INTERFERON REGULATORY FACTORS; LYMPHOMA, PRIMARY CUTANEOUS ANAPLASTIC LARGE CELL; LYMPHOMATOID PAPULOSIS; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; MYCOSIS FUNGOIDES; PROTO-ONCOGENE PROTEINS C-BCL-2; TNF RECEPTOR-ASSOCIATED FACTOR 1; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 67650001917     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2009.09147.x     Document Type: Article

References (25)

1. Willemze R, Jaffe ES, Burg G et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005 105 : 3768 85.
2. Bekkenk MW, Geelen FA, van Vorst Vader PC et al. Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment. Blood 2000 95 : 3653 61.
3. Medeiros LJ, Elenitoba-Johnson KS. Anaplastic large cell lymphoma. Am J Clin Pathol 2007 127 : 707 22.
4. Liu HL, Hoppe RT, Kohler S et al. CD30+ cutaneous lymphoproliferative disorders: the Stanford experience in lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma. J Am Acad Dermatol 2003 49 : 1049 58.
5. Stein H, Foss HD, Durkop H et al. CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood 2000 96 : 3681 95.
6. Assaf C, Hirsch B, Wagner F et al. Differential expression of TRAF1 aids in the distinction of cutaneous CD30-positive lymphoproliferations. J Invest Dermatol 2007 127 : 1898 904.
7. Kempf W, Kutzner H, Cozzio A et al. MUM1 expression in cutaneous CD30+ lymphoproliferative disorders: a valuable tool for the distinction between lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. Br J Dermatol 2008 158 : 1280 7.
8. Paulli M, Berti E, Boveri E et al. Cutaneous CD30+ lymphoproliferative disorders: expression of bcl-2 and proteins of the tumor necrosis factor receptor superfamily. Hum Pathol 1998 29 : 1223 30.
9. Wasco MJ, Fullen D, Su L et al. The expression of MUM1 in cutaneous T-cell lymphoproliferative disorders. Hum Pathol 2008 39 : 557 63.
10. Jaffe ES, Harris NL, Stein H, Vardiman JW. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon : IARC Press, 2001.
11. Durkop H, Foss HD, Demel G et al. Tumor necrosis factor receptor-associated factor 1 is overexpressed in Reed-Sternberg cells of Hodgkin's disease and Epstein-Barr virus-transformed lymphoid cells. Blood 1999 93 : 617 23.
12. Rodig SJ, Savage KJ, Nguyen V et al. TRAF1 expression and c-Rel activation are useful adjuncts in distinguishing classical Hodgkin lymphoma from a subset of morphologically or immunophenotypically similar lymphomas. Am J Surg Pathol 2005 29 : 196 203. (Pubitemid 40170637)
13. Zapata JM, Krajewska M, Krajewski S et al. TNFR-associated factor family protein expression in normal tissues and lymphoid malignancies. J Immunol 2000 165 : 5084 96.
14. Falini B, Fizzotti M, Pucciarini A et al. A monoclonal antibody (MUM1p) detects expression of the MUM1/IRF4 protein in a subset of germinal center B cells, plasma cells, and activated T cells. Blood 2000 95 : 2084 92.
15. Iida S, Rao PH, Butler M et al. Deregulation of MUM1/IRF4 by chromosomal translocation in multiple myeloma. Nat Genet 1997 17 : 226 30.
16. Tsuboi K, Iida S, Inagaki H et al. MUM1/IRF4 expression as a frequent event in mature lymphoid malignancies. Leukemia 2000 14 : 449 56.
17. Valsami S, Pappa V, Rontogianni D et al. A clinicopathological study of B-cell differentiation markers and transcription factors in classical Hodgkin's lymphoma: a potential prognostic role of MUM1/IRF4. Haematologica 2007 92 : 1343 50.
18. Feldman AL, Law M, Remstein ED et al. Recurrent translocations involving the IRF4 oncogene locus in peripheral T-cell lymphomas. Leukemia 2009 23 : 574 80.
19. Goteri G, Simonetti O, Rupoli S et al. Differences in survivin location and Bcl-2 expression in CD30+ lymphoproliferative disorders of the skin compared with systemic anaplastic large cell lymphomas: an immunohistochemical study. Br J Dermatol 2007 157 : 41 8.
20. van Haselen CW, Vermeer MH, Toonstra J et al. p53 and bcl-2 expression do not correlate with prognosis in primary cutaneous large T-cell lymphomas. J Cutan Pathol 1997 24 : 462 7.
21. Carbone A, Gloghini A, Volpe R. Immunohistochemistry of Hodgkin and non-Hodgkin lymphomas with emphasis on the diagnostic significance of the BNH9 antibody reactivity with anaplastic large cell (CD30 positive) lymphomas. Cancer 1992 70 : 2691 8.
22. Benharroch D, Meguerian-Bedoyan Z, Lamant L et al. ALK-positive lymphoma: a single disease with a broad spectrum of morphology. Blood 1998 91 : 2076 84.
23. Gorczyca W, Tsang P, Liu Z et al. CD30-positive T-cell lymphomas co-expressing CD15: an immunohistochemical analysis. Int J Oncol 2003 22 : 319 24.
24. Feldman AL, Dogan A. Diagnostic uses of Pax5 immunohistochemistry. Adv Anat Pathol 2007 14 : 323 34.
25. Vergier B, Beylot-Barry M, Pulford K et al. Statistical evaluation of diagnostic and prognostic features of CD30+ cutaneous lymphoproliferative disorders: a clinicopathologic study of 65 cases. Am J Surg Pathol 1998 22 : 1192 202.